<DOC>
	<DOCNO>NCT02424253</DOCNO>
	<brief_summary>This randomize , double blind , placebo control , parallel group study approximately 90 subject moderate-severe AD Eczema Area Severity Index ( EASI ) ≥12 ≤ 48 ( 0-72 scale ) . Following run-in subject randomize receive either oral 30 mg ZPL-3893787 daily ( od ) placebo od 8 week ( 56 day ) .</brief_summary>
	<brief_title>A Study Determine Efficacy ZPL-3893787 Subjects With Atopic Dermatitis</brief_title>
	<detailed_description>This randomize , double blind , placebo control , parallel group study approximately 90 subject ( 60:30 active : placebo group respectively ) pruritus Numerical Rating Scale ( NRS ) score ≥5 ( 0-10 scale ) , Investigator 's Global Assessment ( IGA ) &gt; 3 ( 0-5 scale ) moderate-severe AD Eczema Area Severity Index ( EASI ) ≥12 ≤ 48 ( 0-72 scale ) . Each subject screen visit ( ) confirm suitability enter study . At subsequent visit ( start Run In ) , subject provide electronic diary ( eDiary ) capture pruritus , sleep disturbance emollient use , must complete Days -7 -1 ( Run In ) . Subjects attend clinic Baseline ( Day 0 ) review confirm meet inclusion/exclusion criterion complete Run In diary appropriately . If appropriate , randomized receive either oral 30 mg ZPL-3893787 daily ( od ) placebo od 8 week ( 56 day ) .</detailed_description>
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<criteria>Males female age 1865 year inclusive physician document history diagnosis atopic dermatitis least 12 month prior screen . Chronic AD diagnose Eichenfield revise criterion Hanifin Rajka ( Eichenfield , 2004 ) Eczema Area Severity Index ( EASI ) ≥12 &lt; 48 . An Investigator 's Global Assessment ( IGA ) score ≥ 3 Screening Day 0 . A mean pruritus score ≥ 5 010 scale 7 day Run In ( Days 7 1 ) Atopic dermatitis affect ≥10 % BSA AD severity ( EASI &gt; 48 ) subject could comply demand study and/or subject suitable candidate placebocontrolled study Have concurrent skin disease ( e.g . acne ) severity study area could interfere study evaluation presence skin comorbidities may interfere study assessment . Have active skin infection clinically apparent infection . Hypersensitivity mometasone ingredient contain topical corticosteroid product use rescue medication study . Have receive phototherapy ( e.g . UVA , UVB ) , systemic therapy ( e.g . immunosuppressant , cytostatics ) know suspected effect AD , within 4 week start Run In . Have receive systemic corticosteroid ( [ CS ] e.g . oral , intravenous , intraarticular , rectal ) within 4 week start Run . Subjects stable maintenance dose ( precede 3 month ) inhale intranasal CS may participate . Were treated oral antihistamine topical calcineurin inhibitor topical steroid within 7 day start Run In ; intranasal antihistamine treatment allergic rhinitis acceptable .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>